China To Impose Export-Licensing Requirement On Drug Industry
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration is about to test a new system of controlling drug exports on 10 pharmaceutical categories, according to the agency's director. Shao Mingli told a national food and drug conference the system would cover pharmaceutical agents and materials used to make them, plus other materials qualified for producing drugs. The new rules would require drug makers to obtain a license and register the drugs they produce, and they would have to have official qualifications and written export approval from authorities before the products can be exported. Shao also vowed to continue a crackdown on bribery, negligence and other abuses linked to the agency. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.